MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$27,294K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Net cash and restricted cash acq...
Gains on acquisitions
Net cash and restricted cash acq...
Others
Negative Cash Flow Breakdown
Other general and administrative...
Gains on acquisitions
Payment for bioinvent contract-b...
Others
Subscribe for Financial Insights
Page 1
Annual
123
Page 1
Cash Flow
2025-12-31
Income and revenues
52,149
Business development and deal related costs
6,654
Research and development expenses
1,712
Depreciation of property and equipment
11
Other general and administrative expenses
29,427
Amortization of intangible assets
2,961
Gains on acquisitions
21,224
Change in fair value of derivatives related to castle creek
93
Interest expense
13,031
Other income, net
12,145
Income tax (expense) benefit
103
Net income (loss)
31,712
Adjustment for income from eir method purchased receivables
-5,925
Stock-based compensation expense
9,273
Gains on acquisitions
21,224
Gain on sale of equity securities
3,663
U.s. federal statutory tax rate
6,681
Foreign tax effects
103
Changes in valuation allowances
-2,538
Stock based compensation
-584
Nondeductible executive compensation
735
Bargain purchase gain
4,457
Other permanent differences
163
Income tax expense (benefit)
103
Common stock contribution to 401
141
Amortization of intangible assets
2,961
Depreciation
11
Accretion of long-term debt discount and debt issuance costs
1,385
Non-cash lease expense
-64
Change in fair value of equity securities
90
Change in fair value of available-for-sale debt securities classified as cash equivalents
-20
Change in fair value of derivatives
93
Cvr liability working capital adjustment
394
Trade and other receivables, net
2,426
Prepaid expenses and other assets
-3,839
Accounts payable and accrued liabilities
-10,597
Operating lease liabilities
-876
Unearned revenue recognized under units-of-revenue method
-1,310
Net cash provided by (used in) operating activities
2,871
Net cash acquired in acquisition-Turnstone Biologics Corp
3,850
Net cash and restricted cash acquired in acquisition-Hillevax Inc
46,384
Net cash and restricted cash acquired in acquisition-Lava Therapeutics Nv
15,263
Net cash and restricted cash acquired in acquisition-Mural Oncology Plc
4,464
Payments of consideration under rpas, aaas, and cppas
8,000
Receipts under rpas, aaas, and cppas
3,300
Payment for bioinvent contract-based intangible asset
20,725
Payment of contingent consideration related to kinnate ip asset
550
Purchase of equity securities
99
Sale of equity securities
6,999
Payment to issue short-term loan to xeno
5,877
Receipt from short-term loan repayment by xeno
5,877
Net cash provided by (used in) investing activities
50,886
Proceeds from issuance of common stock
323
Proceeds from issuance of preferred stock
4,019
Payments of preferred and common stock issuance and financing costs
672
Principal payments - debt
10,598
Debt issuance costs and loan fees paid in connection with long-term debt
80
Payment of preferred stock dividends
5,472
Repurchases of common stock
16,043
Proceeds from exercise of options and other share-based compensation
5,046
Taxes paid related to net share settlement of equity awards
2,986
Net cash used in financing activities
-26,463
Net increase (decrease) in cash, cash equivalents, and restricted cash
27,294
Cash, cash equivalents, and restricted cash as of the beginning of the period
106,416
Cash, cash equivalents, and restricted cash as of the end of the period
133,710
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS).
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Income and revenues
$52,149K
U.s. federal
statutory tax rate
$6,681K
Gains on acquisitions
$21,224K
Other income, net
$12,145K
Change in fair value of
derivatives related to...
$93K
Nondeductible executive
compensation
$735K
Other permanent
differences
$163K
Foreign tax effects
$103K
Net cash and
restricted cash acquired in...
$46,384K
Net cash and
restricted cash acquired in...
$15,263K
Net income (loss)
$31,712K
Sale of equity
securities
$6,999K
Receipt from short-term
loan repayment by...
$5,877K
Net cash and
restricted cash acquired in...
$4,464K
Net cash acquired in
acquisition-Turnstone Biologics Corp
$3,850K
Receipts under rpas,
aaas, and cppas
$3,300K
Stock-based compensation
expense
$9,273K
Prepaid expenses and
other assets
-$3,839K
Amortization of intangible
assets
$2,961K
Accretion of long-term
debt discount and...
$1,385K
Common stock
contribution to 401
$141K
Income tax expense
(benefit)
$103K
Non-cash lease expense
-$64K
Depreciation
$11K
Canceled cashflow
$53,899K
Canceled cashflow
$7,579K
Net cash provided by
(used in) investing...
$50,886K
Net cash provided by
(used in) operating...
$2,871K
Canceled cashflow
$35,251K
Canceled cashflow
$46,618K
Other general and
administrative expenses
$29,427K
Interest expense
$13,031K
Business development and
deal related costs
$6,654K
Amortization of intangible
assets
$2,961K
Research and development
expenses
$1,712K
Income tax (expense)
benefit
$103K
Depreciation of property and
equipment
$11K
Bargain purchase gain
$4,457K
Changes in valuation
allowances
-$2,538K
Stock based
compensation
-$584K
Net increase
(decrease) in cash, cash...
$27,294K
Canceled cashflow
$26,463K
Payment for bioinvent
contract-based intangible...
$20,725K
Payments of
consideration under rpas,...
$8,000K
Payment to issue
short-term loan to xeno
$5,877K
Payment of contingent
consideration related to...
$550K
Purchase of equity
securities
$99K
Proceeds from exercise of
options and other...
$5,046K
Proceeds from issuance of
preferred stock
$4,019K
Proceeds from issuance of
common stock
$323K
Gains on acquisitions
$21,224K
Accounts payable and
accrued liabilities
-$10,597K
Adjustment for income from
eir method...
-$5,925K
Gain on sale of equity
securities
$3,663K
Trade and other
receivables, net
$2,426K
Unearned revenue
recognized under...
-$1,310K
Operating lease
liabilities
-$876K
Cvr liability
working capital...
$394K
Change in fair value of
derivatives
$93K
Change in fair value of
equity securities
$90K
Change in fair value of
available-for-sale debt securities...
-$20K
Net cash used in
financing activities
-$26,463K
Canceled cashflow
$9,388K
Repurchases of common stock
$16,043K
Principal payments - debt
$10,598K
Payment of preferred
stock dividends
$5,472K
Taxes paid related to
net share...
$2,986K
Payments of preferred and
common stock issuance...
$672K
Debt issuance costs
and loan fees paid in...
$80K
Buy us a coffee
XOMA Royalty Corp (XOMA)
XOMA Royalty Corp (XOMA)